Piramal Enterprises is currently trading at Rs. 1876.00, up by 13.35 points or 0.72% from its previous closing of Rs. 1862.65 on the BSE.
The scrip opened at Rs. 1863.60 and has touched a high and low of Rs. 1877.60 and Rs. 1863.60 respectively.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2095.00 on 22-Aug-2016 and a 52 week low of Rs. 938.00 on 18-Mar-2016.
Last one week high and low of the scrip stood at Rs. 1904.00 and Rs. 1851.35 respectively. The current market cap of the company is Rs. 32,372.00 crore.
The promoters holding in the company stood at 51.44%, while Institutions and Non-Institutions held 30.95% and 17.61% respectively.
Piramal Enterprises’ (PEL) wholly owned Critical Care subsidiary in UK has completed its acquisition of a portfolio of drugs for spasticity and pain management from Mallinckrodt LLC (Mallinckrodt). The acquisition was for a cash consideration of $171 million and up to an additional $32 million payable depending on financial performance of the acquired assets over the next three years.
The portfolio acquired includes Gablofen (baclofen), a severe spasticity management product, which is currently marketed in the United States, and two pain management products, which are currently under development. Gablofen has also been approved for launch in eight European markets. In the twelve months ending September 30, 2016, the acquired portfolio generated revenues of $44.6 million.
Piramal Enterprises is one of India’s large diversified companies, with a presence in Pharmaceuticals, Healthcare Information Management and Financial Services.